Tristetraprolin down-regulates IL-23 expression in colon cancer cells

Molecules and Cells

Volumn 36, Issue 6, 2013, Pages 571-576

  Lee, Hyun Hee ^a,b   Yang, Song Soo ^c   Vo, Mai Tram ^a   Cho, Wha Ja ^c   Lee, Byung Ju ^a   Leem, Sun Hee ^b   Lee, Sang Hyun ^c   Cha, Hee Jeong ^c   Park, Jeong Woo ^a  

^a University of Ulsan   (South Korea)

^b Dong A University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

ARE binding protein; Cancer cells; Gene regulation; IL 23; TTP

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; INTERLEUKIN 23; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA; TRISTETRAPROLIN;

ARTICLE; AU RICH ELEMENT; CANCER CELL; COLON CANCER; CYTOKINE PRODUCTION; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOBLOTTING; INFLAMMATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNOLOGY;

3' UNTRANSLATED REGIONS; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTERLEUKIN-23; MICE; POINT MUTATION; RNA STABILITY; RNA, MESSENGER; SEQUENCE DELETION; TRISTETRAPROLIN;

EID: 84900437652     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-013-0268-6     Document Type: Article

References (35)

1. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney, A.L. (2003). Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914. (Pubitemid 36801431)
2. Anderson, P. (2008). Post-transcriptional control of cytokine production. Nat. Immunol. 9, 353-359.
3. Brennan, S.E., Kuwano, Y., Alkharouf, N., Blackshear, P.J., Gorospe, M., and Wilson, G.M. (2009). The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 69, 5168-5176.
4. Carballo, E., Lai, W.S., and Blackshear, P.J. (1998). Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281, 1001-1005. (Pubitemid 28399252)
5. Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S., and Cerami, A. (1986). Identification of a common nucleotide sequence in the 3-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA 83, 1670.
6. Cha, H.J., Lee, H.H., Chae, S.W., Cho, W.J., Kim, Y.M., Choi, H.J., Choi, D.H., Jung, S.W., Min, Y.J., Lee, B.J., et al. (2011). Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer. Hepatogastroenterology 58, 790-795.
7. Chrestensen, C.A., Schroeder, M.J., Shabanowitz, J., Hunt, D.F., Pelo, J.W., Worthington, M.T., and Sturgill, T.W. (2004). MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J. Biol. Chem. 279, 10176-10184. (Pubitemid 38372622)
8. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748. (Pubitemid 36227625)
9. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132. (Pubitemid 41541790)
10. Hunter, C.A. (2005). New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531.
11. Joe, Y., Kim, H.J., Kim, S., Chung, J., Ko, M.S., Lee, W.H., Chang, K.C., Park, J.W., and Chung, H.T. (2011). Tristetraprolin mediates anti-inflammatory effects of nicotine in lipopolysaccharide-stimulated macrophages. J. Biol. Chem. 286, 24735-24742.
12. Kesselring, R., Thiel, A., Pries, R., Trenkle, T., and Wollenberg, B. (2010). Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br. J. Cancer 103, 1245-1254.
13. Kim, C.W., Kim, H.K., Vo, M.T., Lee, H.H., Kim, H.J., Min, Y.J., Cho, W.J., and Park, J.W. (2010) Tristetraprolin controls the stability of cIAP2 mRNA through binding to the 3′UTR of cIAP2 mRNA. Biochem. Biophys. Res. Commun. 400, 46-52.
14. Langowski, J.L., Zhang, X., Wu, L., Mattson, J.D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R.A., and Oft, M. (2006). IL-23 promotes tumour incidence and growth. Nature 442, 461-465. (Pubitemid 44264796)
15. Langrish, C.L., Mckenzie, B.S., Wilson, N.J., de Waal Malefyt, R., Kastelein, R.A., and Cua, D.J. (2004). IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96-105. (Pubitemid 39576907)
16. Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240. (Pubitemid 40189432)
17. Lee, H.H., Son, Y.J., Lee, W.H., Park, Y.W., Chae, S.W., Cho, W.J., Kim, Y.M., Choi, H.J., Choi, D.H., Jung, S.W., et al. (2010a). Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int. J. Cancer 126, 1817-1827.
18. Lee, H.H., Vo, M.T., Kim, H.J., Lee, U.H., Kim, C.W., Kim, H.K., Ko, M.S., Lee, W.H., Cha, S.J., Min, Y.J., et al. (2010b). Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin. J. Biol. Chem. 285, 17329-17337.
19. Lee, W.H., Lee, H.H., Vo, M.T., Kim, H.J., Ko, M.S., Im, Y.C., Min, Y.J., Lee, B.J., Cho, W.J., and Park, J.W. (2011). Casein kinase 2 regulates the mRNA-destabilizing activity of tristetraprolin. J. Biol. Chem. 286, 21577-21587.
20. Lee, H.H., Yoon, N.A., Vo, M.T., Kim, C.W., Woo, J.M., Cha, H.J., Cho, Y.W., Lee, B.J., Cho, W.J., and Park, J.W. (2012). Tristetraprolin down-regulates IL-17 through mRNA destabilization. FEBS Lett. 586, 41-46.
21. Lee, H.H., Kim, W.T., Kim, D.H., Park, J.W., Kang, T.H., Chung, J.W., and Leem, S.H (2013). Tristetraprolin suppresses AHRR expression through mRNA destabilization. FEBS Lett. 587, 1518-1523.
22. Lykke-Andersen, J., and Wagner, E. (2005). Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. Genes Dev. 19, 351-361. (Pubitemid 40189298)
23. Mahtani, K.R., Brook, M., Dean, J.L., Sully, G., Saklatvala, J., and Clark, A.R. (2001). Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell Biol. 21, 6461-6469. (Pubitemid 32927414)
24. Martin-Orozco, N., and Dong, C. (2009). The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr. Opin. Invest. Drugs 10, 543-549.
25. Qian, X., Ning, H., Zhang, J., Hoft, D.F., Stumpo, D.J., Blackshear, P.J., and Liu, J. (2011). Posttranscriptional regulation of IL-23 expression by IFN-γ through tristetraprolin. J. Immunol. 185, 6454-6464.
26. Sauer, I., Schaljo, B., Vogl, C., Gattermeier, I., Kolbe, T., Müller, M., Blackshear, P.J., and Kovarik, P. (2006). Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107, 4790-4797. (Pubitemid 43882630)
27. Schaljo, B., Kratochvill, F., Gratz, N., Sadzak, I., Sauer, I., Hammer, M., Vogl, C., Strobl, B., Müller, M., Blackshear, P.J., et al. (2009). Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J. Immunol. 183, 1197-1206.
28. Shyu, A.B., and Wilkinson, M.F. (2000). The double lives of shuttling mRNA binding proteins. Cell 102, 135-138.
29. Stoecklin, G., and Anderson, P. (2006). Posttranscriptional mechanisms regulating the inflammatory response. Adv. Immunol. 89, 1-37.
30. Stoecklin, G., Stubbs, T., Kedersha, N., Wax, S., Rigby, W.F., Blackwell, T.K., and Anderson, P. (2004). MK2-induced tristetraprolin: 14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J. 23, 1313-1324. (Pubitemid 38525003)
31. Taylor, G.A., Carballo, E., Lee, D.M., Lai, W.S., Thompson, M.J., Patel, D.D., Schenkman, D.I., Gilkeson, G.S., Broxmeyer, H.E., Haynes, B.F., et al. (1996). A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4, 445-454. (Pubitemid 26354654)
32. Teng M.W.L., Andrews, D.M., McLaughlin, N., von Scheidt, B., Ngiow, S.F., Möller, A., Hill, G.R., Iwakura, Y., Oft, M., and Smyth, M.J. (2010). IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl. Acad. Sci. USA 107, 8328-8333.
33. Teng, M.W., von Scheidt, B., Duret, H., Towne, J.E., and Smyth, M.J. (2011). Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res. 71, 2077-2086.
34. Terzic, J., Grivennikov, S., Karin, E., and Karin, M. (2010). Inflammation and colon cancer. Gastroenterology 138, 2101-2114.
35. Young, L.E., Sanduja, S., Bemis-Standoli, K., Pena, E.A., Price, R.L., and Dixon, D.A. (2009). The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136, 1669-1679.